Avatrombopag

Introduction

Avatrombopag is a thrombopoietin receptor agonist used to increase platelet counts in patients with chronic liver disease or primary immune thrombocytopenia (ITP). It mimics the action of thrombopoietin, a hormone that stimulates platelet production in the bone marrow.

Uses

Avatrombopag is used for:

Treating chronic immune thrombocytopenia (ITP) in adults who have not responded adequately to other treatments.
Managing thrombocytopenia associated with chronic liver disease in patients scheduled for elective procedures.

Brand Name	Avatrombopag
Type
Weight
Generic	Avatrombopag
Manufacturer
Available in	English বাংলা

Mechanism of Action

Avatrombopag works by binding to and activating the thrombopoietin receptor on megakaryocytes and progenitor cells, leading to increased production and release of platelets from the bone marrow.

How Long Does It Take to Work?

Platelet counts typically begin to increase within 1 to 2 weeks of starting treatment with avatrombopag. The maximum effect on platelet counts is usually observed within 4 to 6 weeks.

Absorption

Avatrombopag is well absorbed following oral administration, with peak plasma concentrations occurring approximately 4 to 6 hours after dosing. The drug's absorption is not significantly affected by food.

Route of Elimination

Avatrombopag is primarily eliminated via the liver. It undergoes extensive metabolism, with only a small fraction excreted unchanged in the urine.

Dosage

Recommended Dosage for Patients with Chronic Liver Disease: Recommended Dose and Duration in Patients with Chronic Liver Disease Scheduled to Undergo a Procedure-

Platelet count less than 40X10⁹/L: 60 mg (3 tablets) for 5 days
Platelet count 40 to less than 50X10⁹/L: 40 mg (2 tablets) for 5 days

Recommended Dosage for Patients with Chronic Immune Thrombocytopenia: Initial Dose Regimen: Begin Avatrombopag at a starting dose of 20mg (1tablet) once daily with food. Avatrombopag Dose Adjustments for Patients with Chronic Immune Thrombocytopenia-

Less than 50 after at least 2 weeks of Avatrombopag x 10⁹/L: Increase One Dose Level. Wait 2 weeks to assess the effects of this regimen and any subsequent dose adjustments.

Between 200 and 400 x 10⁹/L: Decrease One Dose Level. Wait 2 weeks to assess the effects of this regimen and any subsequent dose adjustments.

Greater than 400 x 10⁹/L: Stop Avatrombopag. Increase platelet monitoring to twice weekly. When platelet count is less than 150 x10 9 /L, decrease One Dose Level per Table 3 and reinitiate therapy.

Less than 50 after 4 weeks of Avatrombopag 40 mg once daily x 10⁹/L: Discontinue Avatrombopag.

Greater than 400 after 2 weeks of Avatrombopag 20 mg weekly x 10⁹/L: Discontinue Avatrombopag.

Or, as directed by the registered physician.

For chronic immune thrombocytopenia (ITP):

Starting dose: 20 mg once daily.
Adjustments may be necessary based on platelet counts and patient response.

For chronic liver disease:

Starting dose: 40 mg once daily.
Adjustments are made based on platelet response and liver function.

Administration

Avatrombopag is administered orally in the form of tablets. It should be taken with or without food at the same time each day to maintain consistent plasma levels.

Side Effects

Common side effects include:

Headache
Nausea
Fatigue
Abdominal pain

Serious side effects may include:

Hepatotoxicity
Thrombotic events

Toxicity

Toxicity can occur with overdose or prolonged use, leading to severe thrombocytosis or thrombotic complications. Symptoms may include dizziness, chest pain, or signs of thrombosis.

Precautions

Precautions include:

Monitoring platelet counts regularly to prevent excessive increases.
Assessing liver function periodically due to the risk of hepatotoxicity.
Evaluating for signs of thrombotic events.

Interaction

Drug interactions may occur with:

Medications that affect platelet function or increase bleeding risk.
CYP3A4 inhibitors or inducers, as they may alter avatrombopag levels.

Disease Interaction

Use with caution in:

Patients with liver disease due to the potential for hepatotoxicity.
Patients with a history of thrombotic events.

Drug Interaction

Interactions include:

Anticoagulants or antiplatelet agents, which may enhance bleeding risk.
Drugs that alter CYP3A4 enzyme activity, affecting avatrombopag metabolism.

Food Interactions

Avatrombopag can be taken with or without food, as food does not significantly affect its absorption.

Pregnancy Use

The safety of avatrombopag during pregnancy is not well established. It should be used only if the potential benefit justifies the potential risk to the fetus.

Lactation Use

It is not known whether avatrombopag is excreted in breast milk. Caution is advised when administering to breastfeeding women, and a risk-benefit assessment should be made.

Acute Overdose

In the case of acute overdose:

Monitor for symptoms of thrombocytosis and thrombotic events.
Provide symptomatic treatment and supportive care as needed.

Contraindication

Contraindications include:

Known hypersensitivity to avatrombopag or any component of the formulation.
Active or recent thrombotic events without appropriate management.

Use Direction

Take avatrombopag exactly as prescribed, with or without food. Do not alter the dose without consulting a healthcare provider.

Storage Conditions

Store avatrombopag at room temperature, away from moisture and heat. Keep out of reach of children.

Volume of Distribution

The volume of distribution for avatrombopag is approximately 50 L, indicating extensive distribution in body tissues.

Half Life

The half-life of avatrombopag is approximately 7 to 9 hours, which supports its once-daily dosing regimen.

Clearance

Avatrombopag is primarily cleared through hepatic metabolism, with minimal renal excretion. The clearance rate is affected by liver function and enzyme activity.

See in details version Avatrombopag also Avatrombopag in bangla